Search Results for "Brian Groves Pfizer Bio"

17:19 EDT 24th October 2014 | BioPortfolio

Original Source: Advil® Launches Advil® Relief in Action Campaign Celebrating Active Volunteers Who Don’t Let Pain Hold Them Back

Pfizer Consumer Healthcare (NYSE: PFE), makers of Advil®, is kicking off its Advil® Relief in Action campaign today that honors volunteers who don’t let pain get in the way of providing relief to others in need. Advil® Relief in Action celebrates the efforts of these tireless everyday heroes, as well as supports and contributes to the efforts of Habitat for Humanity and Wounded Warrior Project® (WWP), whose volunteers exemplify Relief in Action and work...

Matching Channels


Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have ...

CTLA4 Mab rDNA Pfizer

Insulin rDNA inhaled Pfizer

Lymphocyte Immune Globulin Pfizer

Somatropin Hgh rDNA Pfizer

What is GENOTROPIN? GENOTROPIN (somatropin [rDNA origin] for injection) is a growth hormone treatment. It is an exact copy of the natural growth hormone that our bodies make. The main difference i...

Matching News

Pfizer-AZ Saga Spins Off Other Concerns Too

According to an article in Fierce Biotech this morning, there seems little liklihood that anything will stop Pfizer from completing a purchase of AstraZeneca -- it's almost inevitable. Really, it come...

Pfizer leaves investors guessing on intentions for Astra

Pfizer Inc , which in May abandoned its $118 billion bid to buy AstraZeneca Plc , on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considerin...

Pfizer Has It All Wrong, Should Look Into New Viable Acquisitions

By Long Term Bio:Pfizer (PFE) had recently announced that it was unable to reach a deal to merge with AstraZeneca (AZN). The final bid Pfizer gave was $116 billion dollars, and the company stated that...

AstraZeneca rejects Pfizer’s final offer, again

On Friday May 16th, 2014, Pfizer announces its final proposal to combine the two companies. This is the fourth proposal Pfizer has made and Pfizer believes that this final proposal provides a clear ba...

Is Pfizer’s next acquisition target, Activas?

Bloomberg reports, Pfizer is looking at Actavis, the generics maker with a new home address in Ireland, among other targets. Pfizer may not get a great shot at buying AstraZeneca this fall–but...

Pfizer to Acquire InnoPharma

Pfizer and InnoPharma, a privately held pharmaceutical development company, today announced that they have entered into an agreement under which Pfizer will acquire InnoPharma.Under the terms of the a...

You blew it, Pfizer tells AstraZeneca

Just ahead of the deadline of 5pm 26 May (UK time), Pfizer confirmed the news that everyone had been expecting. Following AstraZeneca's rebuttal of Pfizer's "final" acquisition proposal of 18 May, Pfi...

InnoPharma has entered into m&a with Pfizer

Pfizer and InnoPharma have entered into an m&a agreement under which Pfizer will acquire InnoPharma. Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 mil...

Matching PubMed Articles

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement